<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00476281</url>
  </required_header>
  <id_info>
    <org_study_id>3887</org_study_id>
    <nct_id>NCT00476281</nct_id>
  </id_info>
  <brief_title>Nutritional, Metabolic and Respiratory Status in Cystic Fibrosis</brief_title>
  <official_title>Multicenter Prospective Study of Abnormalies Tolerance Glucose by the Continuous Measurement of Glucose of Nutritional Status and Breathing in the Patient With Cystic Fibrosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Strasbourg, France</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Association d'Aide aux Insuffisants Respiratoires d'Alsace Lorraine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Strasbourg, France</source>
  <brief_summary>
    <textblock>
      Diabetes is a important complication of cystic fibrosis (CF). The improved life expectancy of
      patients with cystic fibrosis, as a result of advances in medical therapy, has resulted in an
      increasing prevalence of cystic fibrosis-related diabetes (CFRD). CFRD is associated with
      accelerated pulmonary decline and increased mortality. Pulmonary effects are seen some years
      before the diagnosis of CFRD implying that impaired glucose tolerance may be very early
      detrimental. Insulin treatment is clearly indicated in patients with CFRD to control symptoms
      and reduce complications. However, at the state of impaired glucose tolerance or fasting
      hyperglycaemia, current screening methods are not suitable for the early management of
      hyperglycaemia.The recent introduction of the continuous glucose monitoring system (CGMS),
      which provides a continuous glucose profile, has revealed to be clinically relevant in the
      investigation of glucose excursions over a long period. This device, widely use in diabetic
      non cystic fibrosis patients, has been validated in non diabetic cystic fibrosis subjects.
      Previous studies of continuous glucose monitoring have been realized in CF patients with
      normal glucose tolerance and diabetes and compared with non CF controlThe aim of our study is
      to evaluate the glucose profile with continuous glucose monitoring the nutritional and
      respiratory status in cystic fibrosis subjects, according to their glucose tolerance.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2008</start_date>
  <completion_date type="Actual">January 2020</completion_date>
  <primary_completion_date type="Actual">January 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>nutritional and respiratory parameters</measure>
    <time_frame>five years</time_frame>
    <description>descriptive comparison of nutritional and respiratory parameters in function abnormalities glucose tolerance.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>abnormal glucose tolerance</measure>
    <time_frame>five tears</time_frame>
    <description>assess the prevalence of abnormal glucose tolerance.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">114</enrollment>
  <condition>Cystic Fibrosis</condition>
  <condition>Diabetes</condition>
  <arm_group>
    <arm_group_label>abnormal glucose tolerance</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>abnormal glucose tolerance</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Urinary collect</intervention_name>
    <arm_group_label>abnormal glucose tolerance</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Continuous Glucose Monitoring System (CGMS)</intervention_name>
    <arm_group_label>abnormal glucose tolerance</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  patients 10 years and older with cystic fibrosis

          -  not known diabetics with fasting blood glucose &lt;1.26 g / l

          -  outside periods of exacerbation and / or glucocorticoid therapy

          -  affiliated to a social security scheme

          -  having received the results of the mandatory medical examination

          -  having signed an informed consent

        Exclusion Criteria:

          -  Patient transplanted lung and / or liver

          -  Subject during participation in an interventional clinical trial

          -  unable to give informed about the information

          -  patient under judicial protection

          -  patient under tutorship or curatorship

          -  pregnancy

          -  breastfeeding

          -  patient treated with the combination lumacaftor and ivacaftor
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>10 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Laurence KESSLER, MD</last_name>
    <role>Study Director</role>
    <affiliation>Hôpitaux Universitaires de Strasbourg</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Centre Robert Debré - CHU Angers</name>
      <address>
        <city>Angers</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service d'Endocrinologie et Métabolisme - CHRU de Lille</name>
      <address>
        <city>Lille</city>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Laennec - CHU de Nantes</name>
      <address>
        <city>Nantes</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service de Pédiatrie A - CHU de Reims</name>
      <address>
        <city>Reims</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CRCM Centre de Perharidy</name>
      <address>
        <city>Roscoff</city>
        <zip>29684</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service d'Endocrinologie, Diabète et Maladies Métaboliques - Hôpital Civil</name>
      <address>
        <city>Strasbourg</city>
        <zip>67091</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service de Réanimation Médicale - Hôpital Civil</name>
      <address>
        <city>Strasbourg</city>
        <zip>67091</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service de Pneumologie - Hôpital de Hautepierre</name>
      <address>
        <city>Strasbourg</city>
        <zip>67098</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service de Pédiatrie II</name>
      <address>
        <city>Strasbourg</city>
        <zip>67098</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>May 18, 2007</study_first_submitted>
  <study_first_submitted_qc>May 18, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 21, 2007</study_first_posted>
  <last_update_submitted>April 24, 2020</last_update_submitted>
  <last_update_submitted_qc>April 24, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 28, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cystic Fibrosis</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

